A Clinical Trial to Evaluate the Safety and Immunogenicity of Glycan-trimmed HIV-1 Nanoparticle Vaccine (UVAX-1107), Followed by Homologous or Wild-type HIV-1 Nanoparticle Vaccine (UVAX-1197) Boost, Each Adjuvanted With 3M-052-AF + Alum in Adult Participants Without HIV

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

SUSPENDED

Clinical Phase

PHASE1

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-07-07

Study Completion Date

2027-07-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a phase 1, first-in-human (FIH) trial for the combination of UVAX-1107 and UVAX-1197, both adjuvanted with 3M-052-AF + Aluminum Hydroxide Suspension (Alum). This means it is the first time this combination of study products is being tested in people.

The purpose of this study is to see if the study products are safe, if people are able to take them without becoming too uncomfortable, and how a person's immune system responds to them (a person's immune system protects them from infections and disease).

Twenty-five volunteers without HIV and in overall good health will be enrolled and be in this study for a little over 1 year (56 weeks) of clinic visits (about 12 visits), with a follow-up contact 1 year after the final injection to check on their health.

Study procedures will include blood draws, injections, and the collection of white blood cells and cells from their lymph nodes.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Trial in Adult Participants Without HIV and in Overall Good Health to Evaluate the Safety and Immunogenicity of CD4BS CH505M5 Pr-NP1 Followed by CH505 TF chTrimer Boost Both Adjuvanted With Either Lipid Nanoparticles (LNPs) or 3M-052-AF + Alum

NCT06267872

HIV

WITHDRAWN PHASE1

Study to Evaluate the Safety and Immunogenicity of an HIV-1 Vaccine Regimen of Adjuvanted UVAX-1107 Followed by Adjuvanted UVAX-1107 or Adjuvanted UVAX-1197 in Healthy Subjects Aged 25-55 Years.

NCT06541093

COMPLETED EARLY_PHASE1

Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 16055 NFL Delta Gly4 Env Protein Trimer and Trimer 4571 Combined With 3M-052-AF + Alum Adjuvant and Ad4-Env145NFL Viral Particles as Heterologous Prime-boost Regimens in Adult Participants Without HIV.

NCT06332339

HIV

ACTIVE_NOT_RECRUITING PHASE1

Clinical Trial to Evaluate the Safety and Immunogenicity of Ferritin Nanoparticles Expressing Native-like HIV-1 Envelope Trimers Followed by Boost With mRNA Lipid Nanoparticles Encoding a Native-like HIV-1 Envelope Trimer in Adults Without HIV

NCT05903339

Hiv

ACTIVE_NOT_RECRUITING PHASE1

A Phase I, Multicenter, Randomized, Double-Blind, Placebo-Controlled HIV-1 Vaccine Trial to Evaluate the Safety and Immunogenicity of MN Recombinant Soluble gp120/HIV-1 (rsgp120/HIV-1) (Genentech) in Combination With QS21 Adjuvant and/or Alum in Healthy Adults

NCT00001052

HIV Infections

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV-1-infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

The trial will begin with enrollment of Group 1. Groups 2 and 3 will open to enrollment concurrently. Enrollment in Group 2 and Group 3 will be randomized.

Primary Study Purpose

PREVENTION

Blinding Strategy

NONE

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

3M-052-AF + Alum

Intramuscular (IM) injection

Intervention Type BIOLOGICAL

UVAX-1107

IM injection

Intervention Type BIOLOGICAL

UVAX-1197

IM injection

Intervention Type BIOLOGICAL

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Glycan-trimmed Wild Type (WT)

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Understand the study and agree to participate.
* Be available for follow-up visits and contact for 12 months after the last study product is administered.
* Be willing to undergo all study procedures.
* Not be in another study unless approved by both study sponsors.
* Be in good general health.
* Have normal physical exam and lab results.
* Agree to discuss HIV risk and prevention.
* Have a certain minimum hemoglobin level (≥ 11.0 g/dL for women, ≥ 13.0 g/dL for men).
* Have a white blood cell count within 2500 to 12,000/mm³.
* Have a platelet count between 125,000 to 550,000/mm³.
* Have an ALT level less than 2.5 times the upper limit of normal.
* Have a serum creatinine level within 1.1 times the normal limit.
* Have a serum calcium level of at least 8.5 mg/dL.
* Have blood pressure within specified limits.
* Test negative for HIV.
* Test negative for Hepatitis C.
* Test negative for Hepatitis B.
* Women who can become pregnant must use effective contraception and test negative for pregnancy at enrollment.
* Women who can become pregnant must agree not to seek pregnancy through alternative methods during the study period.

Exclusion Criteria

* Breastfeeding or pregnant.
* BMI is 40 or higher (exceptions can be made if you're in good health).
* Diagnosed with diabetes (unless it's well-controlled Type 2 diabetes or gestational diabetes).
* Received an investigational HIV vaccine or monoclonal antibodies.
* Received a non-HIV investigational vaccine in the past year (exceptions exist for licensed or emergency-authorized vaccines).
* Have an immune deficiency or are taking medications that impair immune response.
* Received blood products or immunoglobulins within the last 16 weeks.
* Received certain vaccines within 4 weeks before enrollment.
* Received other vaccines within 14 days before enrollment.
* Started allergy immunotherapy within the last year (stable therapy is okay).
* Taken investigational research agents recently.
* Had a serious reaction to any vaccine.
* Have hereditary or acquired angioedema.
* Had unexplained hives in the past year.
* Have a bleeding disorder that would make study procedures risky.
* Had seizures or taken seizure medication in the past 3 years.
* Spleen has been removed or spleen doesn't work properly.
* Active duty or reserve US military personnel.
* Any serious health condition that could affect safety, rights, or ability to participate (including substance use, psychiatric disorders, recent suicide attempts, or cancer with potential recurrence).
* Asthma that requires frequent or high-dose medication, emergency care, or multiple maintenance therapies.
* History of certain immune-mediated medical conditions (mild, localized conditions may be okay).
* Allergic to local anesthetics like Novocaine or Lidocaine.
* History of difficult venous access or intravenous drug use.

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes